![(aS)-N-[(1S)-2-[[(7S)-6,7-Dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro-alpha-hydroxybenzeneacetamide structure, CAS 209984-57-6](/structures/60000/55483_1_209984_57_6.png)
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 209984-57-6 |
| Catalog No. | 2A-9055483 |
| Chinese Name | (aS)-N-[(1S)-2-[[(7S)-6,7-二氢-5-甲基-6-氧代-5H-二苯并[b,d]氮杂卓-7-基]氨基]-1-甲基-2-氧代乙基]-3,5-二氟-alpha-羟基苯乙酰胺 |
| Synonyms | cc-581; LY411575 |
| Molecular Formula | C26H23F2N3O4 |
| Molecular Weight | 479.48 |
| Purity | ≥97 (HPLC) |
| Density | 1.4±0.1 g/cm3 |
| Boiling Point | 836.0±65.0 °C at 760 mmHg |
| Melting Point | 328.47°C |
| Appearance | powder |
| Water Solubility | DMSO: soluble5mg/mL, clear |
| Storage Condition | ?20°C |
| Application | LY-411575 is a highly efficient γ-secretase inhibitor that can inhibit the production of Aβ40 protein with an IC50 value of 0.078 nM/0.082 nM (based on membrane/cell) and inhibit Notch cleavage with a |
| HTC | 29337900 |
| PubChem ID | 329825453 |
| MDL Number | MFCD09832551 |
| SMILES | C[C@H](NC(=O)[C@@H](O)c1cc(F)cc(F)c1)C(=O)N[C@@H]2C(=O)N(C)c3ccccc3-c4ccccc24 |
| InChI | 1S/C26H23F2N3O4/c1-14(29-25(34)23(32)15-11-16(27)13-17(28)12-15)24(33)30-22-20-9-4-3-7-18(20)19-8-5-6-10-21(19)31(2)26(22)35/h3-14,22-23,32H,1-2H3,(H,29,34)(H,30,33)/t14-,22-,23-/m0/s1 |
| InChI Key | ULSSJYNJIZWPSB-CVRXJBIPSA-N |
| NACRES Code | NA.77 |
| UNSPSC | 12352200 |
| Hazard Symbols | transportation |
| MSDS | msds/55483_1_209984_57_6.pdf |
| Bioactivity | LY-411575 is a potent γ-secretase inhibitor with IC50 of 0.078 nM/0.082 nM (membrane/cell-based), and also inhibits Notch S3 cleavage with IC50 of 0.39 nM. Related Catalog Signaling Pathways >> Neuronal Signaling >> γ-secretase Signaling Pathways >> Stem Cell/Wnt >> γ-secretase Signaling Pathways >> Stem Cell/Wnt >> Notch Research Areas >> Neurological Disease Target IC50: 0.078 nM (γ-secretase in membrane), 0.082 nM (γ-secretase cell-based), 0.39 nM (Notch S3 cleavage cell-based)[1] In Vitro LY-411,575 blocks Notch activation, and results in apoptosis in primary and immortalized KS cells. LY-411,575 (500 μM) induces G2/M growth arrest SLK cells[2]. LY411575 treatment significantly decreases the amounts of intracellular HCV RNA with IC50 of 0.56 ± 0.20 μM and extracellular HCV particles. LY411575 (0-40 nM) alone or in combination with daclatasvir (0-40 pM) decreases supernatant infectious titers in a dose-dependent manner, and is synergistic regarding production of infectious virus. LY411575 (10 µM) treatment impairs ROS production in HCVcc-infected cells[4]. LY411575 significantly attenuates EMT by inhibiting the Notch signaling activation in vitro[5]. In Vivo LY-411,575 (10 mg/kg) decreases brain and plasma Aβ40 and -42 robustly when chronically administered to TgCRND8 mice[1]. LY411,575 reduces cortical Aβ40 in young transgenic CRND8 mice (ED50 appr 0.6 mg/kg) and produces significant thymus atrophy and intestinal goblet cell hyperplasia at higher doses (>3 mg/kg). The extent of intestinal goblet cell hyperplasia induced by LY411,575 (10 mg/kg) is similar in young and aged mice[3]. LY411575 inhibits mouse proliferative vitreoretinopathy (PVR) formation in vivo[5]. Animal Admin Mice from the aged cohort (16-26 months old) are either retired breeders or experimentally naive mice. Before dosing begin and for the duration of the study, mice are singly housed with a plastic igloo and nesting material. Mice are sacrificed 2 to 4 h after their final dosing. For oral dosing, LY411,575 and LY-D are formulated as 10 mg/mL solutions and diluted 1:10 with 0.4% methycellulose. In the case of subcutaneous dosing, the 10 mg/mL stock solution is diluted 1:10 with 20% hydroxyl-propyl-β-cyclodextrin. If necessary, serial dilutions are made from the 1 mg/mL solution using the appropriate 1:10 vehicle. The dosing volume is 10 mL/kg. After oral administration of 10 mg/kg LY411,575, inhibition of plasma Aβ is still significant 24, but not 48, h after dosing, so in an effort to maintain continuous γ-secretase inhibition, LY411,575 and LY-D are dosed once per day in all studies. References [1]. Wong GT, et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem. 2004 Mar 26;279(13):12876-82. [2]. Curry CL, et al. Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene. 2005 Sep 22;24(42):6333-44. [3]. Hyde LA, et al. Studies to investigate the in vivo therapeutic window of the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 mouse. J Pharmacol Exp Ther. 2006 Dec;319(3):1133-43. [4]. Otoguro T, et al. Inhibitory effect of presenilin inhibitor LY411575 on maturation of hepatitis C virus core protein, production of the viral particle and expression of host proteins involved in pathogenicity. Microbiol Immunol. 2016 Nov;60(11):740-753 [5]. Zhang J, et al. Notch signaling modulates proliferative vitreoretinopathy via regulating retinal pigment epithelial-to-mesenchymal transition. Histochem Cell Biol. 2017 Mar;147(3):367-375. Chemical & Physical Properties Density 1.4±0.1 g/cm3 Boiling Point 836.0±65.0 °C at 760 mmHg Melting Point 328.47°C Molecular Formula C26H23F2N3O4 Molecular Weight 479.475 Flash Point 459.4±34.3 °C Exact Mass 479.165649 PSA 98.74000 LogP 4.75 Appearance of Characters white to beige Vapour Pressure 0.0±3.2 mmHg at 25°C Index of Refraction 1.652 InChIKey ULSSJYNJIZWPSB-CVRXJBIPSA-N SMILES CC(NC(=O)C(O)c1cc(F)cc(F)c1)C(=O)NC1C(=O)N(C)c2ccccc2-c2ccccc21 Storage condition ?20°C Water Solubility DMSO: soluble5mg/mL, clear |
| Use of | Properties Name ly-411575 Synonym More Synonyms LY-411575 Biological Activity Related Catalog Signaling Pathways >> Neuronal Signaling >> γ-secretase Signaling Pathways >> Stem Cell/Wnt >> γ-secretase Signaling Pathways >> Stem Cell/Wnt >> Notch Research Areas >> Neurological Disease References [1]. Wong GT, et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem. 2004 Mar 26;279(13):12876-82. [2]. Curry CL, et al. Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene. 2005 Sep 22;24(42):6333-44. [4]. Otoguro T, et al. Inhibitory effect of presenilin inhibitor LY411575 on maturation of hepatitis C virus core protein, production of the viral particle and expression of host proteins involved in pathogenicity. Microbiol Immunol. 2016 Nov;60(11):740-753 [5]. Zhang J, et al. Notch signaling modulates proliferative vitreoretinopathy via regulating retinal pigment epithelial-to-mesenchymal transition. Histochem Cell Biol. 2017 Mar;147(3):367-375. Chemical & Physical Properties Molecular Formula C26H23F2N3O4 Exact Mass 479.165649 PSA 98.74000 Appearance of Characters white to beige Index of Refraction 1.652 InChIKey ULSSJYNJIZWPSB-CVRXJBIPSA-N |
| Transport Info | Product name: Purity: 98.0% |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.2 Names specified by the United Nations (UN) European Land Transport Dangerous Regulations: Non-dangerous goods IMDG Code: Non-dangerous goods International air transport dangerous goods regulations: non-dangerous goods 14.3 Transport hazard categories European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.4 Package group European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.5 Environmental hazards European Land Transport Dangerous Regulations: No International Maritime Transport Dangerous Regulations Maritime Pollutants: No International Air Transport Risk Regulations: No 14.6 Special reminder to users No data available See reverse side of invoice or packing slip. |
| Related Products in Specialty Chemicals | ||
|---|---|---|
| Anatibant | 209733-45-9 | 2A-9055474 |
| Entinostat | 209783-80-2 | 2A-9055475 |
| Forodesine | 209799-67-7 | 2A-9055476 |
| Tafluprost | 209860-87-7 | 2A-9055477 |
| 2-Ethyl-2-adamantyl methacrylate | 209982-56-9 | 2A-9055482 |
| 3,4,5-Trifluorophenylacetic acid | 209991-62-8 | 2A-9055484 |
| 2,4,6-Trifluorophenylacetic acid | 209991-63-9 | 2A-9055485 |
| 4-Aminotetrahydro-2H-thiopyran 1,1-dioxide | 210240-20-3 | 2A-9055493 |
| PENT-4-ENYLAMINE HYDROCHLORIDE | 22537-07-1 | 2A-9055495 |
| Sitaxsentan sodium | 210421-74-2 | 2A-9055496 |
| Browse all Specialty Chemicals products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS